ArticleBMC complementary medicine and therapies2025
In vitro antibacterial activity of neochebulinic acid from aqueous extract of Terminalia chebula Retz against Helicobacter pylori.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Indigestible carbohydrates suppress colorectal cancer through IRF6/TRAF3/IFNα pathway.Discover oncology · 2026Article
- Ethnic genomic differences in esophageal squamous cell carcinoma: Whole-exome sequencing of Han and Kazakh populations in China.World journal of gastroenterology · 2025Article
- Regulatory effect of miR-142-5p on inflammatory process of sepsis by targeting CXCL8.Hereditas · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNeochebulinic acid, a component of Terminalia chebula Retz, exhibits diverse biological activities. This study aimed to investigate its anti-Helicobacter pylori (HP) activity. METHODS AND MATERIALS: Through using ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and nuclear magnetic resonance (NMR) spectroscopy, neochebulinic acid was isolated and identified. Efficacy was assessed via minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays, scanning electron microscopy (SEM), and other assays.
resultsIt demonstrated neochebulinic acid’s ability to inhibit HP proliferation, damage bacterial structure, and suppress Cytotoxin-associated gene A (Cag A) protein expression, with high selectivity towards HP. Neochebulinic acid also acts as an anti-adhesive agent, preventing HP adhesion to host cells.
conclusionThese findings suggest its potential as a targeted therapeutic against HP infections, paving the way for novel anti-HP therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.